Research and Development Expenses Breakdown: Merck & Co., Inc. vs Bausch Health Companies Inc.

Merck vs. Bausch: A Decade of R&D Investment

__timestampBausch Health Companies Inc.Merck & Co., Inc.
Wednesday, January 1, 20142460000007180000000
Thursday, January 1, 20155828000006704000000
Friday, January 1, 20164550000007194000000
Sunday, January 1, 20173660000009982000000
Monday, January 1, 20184140000009752000000
Tuesday, January 1, 20194710000009872000000
Wednesday, January 1, 202045200000013397000000
Friday, January 1, 202146500000012245000000
Saturday, January 1, 202252900000013548000000
Sunday, January 1, 202360400000030531000000
Loading chart...

Cracking the code

A Decade of Innovation: R&D Spending in Pharmaceuticals

In the ever-evolving world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Merck & Co., Inc. and Bausch Health Companies Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Merck's R&D expenses surged by over 300%, peaking in 2023 with a staggering $30.5 billion, reflecting its commitment to groundbreaking medical advancements. In contrast, Bausch Health's R&D spending remained relatively stable, with a modest increase of approximately 145% over the same period, reaching $604 million in 2023. This disparity highlights Merck's aggressive pursuit of innovation compared to Bausch Health's more conservative strategy. As the pharmaceutical landscape continues to shift, these investment patterns offer a glimpse into the future of healthcare innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025